Mars Symbioscience, Calithera Biosciences deal

Mars Symbioscience granted Calithera an exclusive, worldwide license to develop and commercialize the division’s portfolio of preclinical arginase inhibitors for use in human healthcare. Calithera said the program will help it submit an IND to FDA by year end for an arginase inhibitor to treat cancer. Calithera is responsible for development and commercialization. ...